74 research outputs found
Determination of the cardiac drug amiodarone and its N-desethyl metabolite in sludge samples
This is the postprint (accepted manuscript) version of the article published in Journal of Chromatography A http://doi.org/10.1016/j.chroma.2015.03.024 This manuscript version is made available under de CC-BY-NC-ND 4.0 licenseFor the first time, a procedure for the simultaneous determination of the iodinated drug amiodarone and its major metabolite, N-desethylamiodarone, in sludge from urban sewage treatment plants (STPs) is proposed. Matrix solid-phase dispersion (MSPD) followed by on-line cationic exchange clean-up, in mod- ular configuration, was used as sample preparation technique. Liquid chromatography with tandem mass spectrometry (LC–MS/MS), based on a hybrid quadrupole time-of-flight (QTOF) system, was employed for the selective determination of target compounds. The optimized procedure provided exhaustive recov- eries with little effect of the sample matrix in the efficiency of electrospray ionization (ESI). The overall recoveries of the method ranged between 95 and 111%, for samples spiked at different concentration levels. The achieved limits of quantification (LOQs) remained below 10 ng g−1 for both compounds, and the linear response range extended up to 2500 ng g−1. Amiodarone and N-desethylamiodarone were ubiquitous in sludge samples, from different STPs located in the Northwest of Spain, with maximum concentrations above 300 ng g−1 referred to the freeze-dried matrix. They were also present in stabilized sludge (mixed with lime and thermally dehydrated), which is mostly disposed in agriculture fields as fertilizer. Furthermore, mono-iodinated analogues of amiodarone and N-desethylamiodarone were also tentatively identified in some samples from their accurate MS and MS/MS spectraThis study has been supported by the Spanish Government and E.U. FEDER funds (project CTQ2012-33080) and the Xunta de Galicia (Excellence Research Groups Programme). R.M. acknowledges a post-doctoral “Juan de la Cierva” contract from the Spanish Ministry of Economy and Competitiveness.S
Maternal Pre-Pregnancy Obesity Is Associated with Altered Placental Transcriptome
Maternal obesity has a major impact on pregnancy outcomes. There is growing evidence that maternal obesity has a negative influence on placental development and function, thereby adversely influencing offspring programming and health outcomes. However, the molecular mechanisms underlying these processes are poorly understood. We analysed ten term placenta's whole transcriptomes in obese (n = 5) and normal weight women (n = 5), using the Affymetrix microarray platform. Analyses of expression data were carried out using non-parametric methods. Hierarchical clustering and principal component analysis showed a clear distinction in placental transcriptome between obese and normal weight women. We identified 72 differentially regulated genes, with most being down-regulated in obesity (n = 61). Functional analyses of the targets using DAVID and IPA confirm the dysregulation of previously identified processes and pathways in the placenta from obese women, including inflammation and immune responses, lipid metabolism, cancer pathways, and angiogenesis. In addition, we detected new molecular aspects of obesity-derived effects on the placenta, involving the glucocorticoid receptor signalling pathway and dysregulation of several genes including CCL2, FSTL3, IGFBP1, MMP12, PRG2, PRL, QSOX1, SERPINE2 and TAC3. Our global gene expression profiling approach demonstrates that maternal obesity creates a unique in utero environment that impairs the placental transcriptome
Changes in plasma total saturated fatty acids and palmitic acid are related to pro-inflammatory molecule IL-6 concentrations after nutritional intervention for one year
Systemic inflammation is associated with an increased risk of non-communicable diseases, such as cardiovascular diseases and diabetes. Circulating fatty acids (FA) are known to be related to these conditions, possibly through their role in inflammation, although different types of FAs can have opposite effects on inflammatory mediators. The aim of the present study was to analyze the association of plasma FAs with inflammatory biomarkers in a PREDIMED trial subsample after one year of intervention. In a one-year longitudinal study of 91 participants of the PREDIMED trial (Barcelona-Clinic center), plasma FAs and inflammatory biomarkers were analyzed using gas chromatography and ELISA, respectively. In baseline plasma, a multivariable-adjusted ordinary least squares regression model showed that n-3 polyunsaturated FAs concentrations were inversely associated with concentrations of soluble intercellular adhesion molecule-1 (sICAM-1) and E-selectin, whereas the level of the most abundant saturated FA, palmitic acid, was directly associated with concentrations of interleukin-6 (IL-6) (β = 0.48 pg/mL, 95% CI: 0.03, 0.93 per 1-SD increase, p-value = 0.037). After one year of nutritional intervention, changes of plasma diet-derived total saturated FAs and palmitic acid were directly associated with changes in IL-6 (β = 0.59 pg/mL [95% CI: 0.28, 0.89] per 1-SD, p-value = 0.001; β = 0.64 pg/mL, 95% CI: 0.31, 0.98, p-value = 0.001), respectively, after correction for multiple testing. Our findings suggest that saturated FAs of dietary origin, especially palmitic acid, are directly involved in the increase of IL-6 in plasma
Infant Formula Supplemented With Milk Fat Globule Membrane, Long-Chain Polyunsaturated Fatty Acids, and Synbiotics Is Associated With Neurocognitive Function and Brain Structure of Healthy Children Aged 6 Years: The COGNIS Study
Background: Adequate nutrient intake during the first few months of life plays a critical role on brain structure and function development. Objectives: To analyze the long-term effects of an experimental infant formula (EF) on neurocognitive function and brain structure in healthy children aged 6 years compared to those fed with a standard infant formula or breastfed. Methods: The current study involved 108 healthy children aged 6 years and participating in the COGNIS Study. At 0-2 months, infants were randomized to receive up to 18 months of life a standard infant formula (SF) or EF enriched with milk fat globule membrane (MFGM), long-chain polyunsaturated fatty acids (LC-PUFAs) and synbiotics. Furthermore, a reference group of breastfed (BF) infants were also recruited. Children were assessed using neurocognitive tests and structural Magnetic Resonance Imaging (MRI) at 6 years old. Results: Experimental infant formula (EF) children showed greater volumes in the left orbital cortex, higher vocabulary scores and IQ, and better performance in an attention task than BF children. EF children also presented greater volumes in parietal regions than SF kids. Additionally, greater cortical thickness in the insular, parietal, and temporal areas were found in children from the EF group than those fed with SF or BF groups. Further correlation analyses suggest that higher volumes and cortical thickness of different parietal and frontal regions are associated with better cognitive development in terms of language (verbal comprehension) and executive function (working memory). Finally, arachidonic acid (ARA), adrenic acid (AdA), docosahexaenoic acid (DHA) levels in cheek cell glycerophospholipids, ARA/DHA ratio, and protein, fatty acid, and mineral intake during the first 18 months of life seem to be associated with changes in the brain structures at 6 years old. Conclusions: Supplemented infant formula with MFGM components, LC-PUFAs, and synbiotics seems to be associated to long-term effects on neurocognitive development and brain structure in children at 6 years old.This project has been funded by Laboratorios Ordesa, S.L. Contract University of Granada General Foundation, No. 3349 and SMARTFOODS (CIEN) Contract University of Granada General Foundation, No. 4003, Spanish Ministry of Economy, Industry and Competitiveness. Furthermore, the project has been partially funded by HORIZON 2020 EU DynaHEALTH Project (GA No. 633595).S
Identification of foods contributing to the dietary lipid profile of a Mediterranean population
Changes in the phenolic content of low density lipoprotein after olive oil consumption in men. A randomized crossover controlled trial
Olive oil decreases the risk of CVD. This effect may be due to the fatty acid profile of the oil, but it may also be due to its antioxidant content which differs depending on the type of olive oil. In this study, the concentrations of oleic acid and antioxidants (phenolic compounds and vitamin E) in plasma and LDL were compared after consumption of three similar olive oils, but with differences in their phenolic content. Thirty healthy volunteers participated in a placebo-controlled, double-blind, crossover, randomized supplementation trial. Virgin, common, and refined olive oils were administered during three periods of 3 weeks separated by a 2-week washout period. Participants were requested to ingest a daily dose of 25 ml raw olive oil, distributed over the three meals of the day, during intervention periods. All three olive oils caused an increase in plasma and LDL oleic acid (P,0·05) content. Olive oils rich in phenolic compounds led to an increase in phenolic compounds in LDL (P, 0·005). The concentration of phenolic compounds in LDL was directly correlated with the phenolic concentration in the olive oils. The increase in the phenolic content of LDL could account for the increase of the resistance of LDL to oxidation, and the decrease of the in vivo oxidized LDL, observed in the frame of this trial. Our results support the hypothesis that a daily intake of virgin olive oil promotes protective LDL changes ahead of its oxidation. Olive oil: Oleic acid: Phenolic compounds: LDL: CVD risk CVD is the main cause of death and disability in developed countries 1 -3 . The type of fat consumed can modify the plasma and LDL lipid profile, which is directly related to the growth of atheroma plaque To date, few studies have analysed the effects of sustained olive oil consumption on human LDL composition. The few available data come from short-term studies Materials and methods Study population An in-person screening visit was conducted to ascertain eligibility and obtain baseline data. Forty-two subjects from a religious community were screened for inclusion. Nine of them were ineligible. Thus, thirty-three healthy volunteers, from 23 to 91 years old, with a regular lifestyle and dietary habits * Corresponding author: Dr M. Carmen López Sabater, fax þ 34-93 403 59 31, email [email protected] Abbreviations: CAE, caffeic acid equivalents; FAME, fatty acid methyl esters
The Effect of Maternal Obesity on Breast Milk Fatty Acids and Its Association with Infant Growth and Cognition—The PREOBE Follow-Up
This study analyzed how maternal obesity affected fatty acids (FAs) in breast milk and
their association with infant growth and cognition to raise awareness about the programming effect
of maternal health and to promote a healthy prenatal weight. Mother–child pairs (n = 78) were
grouped per maternal pre-pregnancy body mass index (BMI): normal-weight (BMI = 18.5–24.99),
overweight (BMI = 25–29.99) and obese (BMI > 30). Colostrum and mature milk FAs were determined.
Infant anthropometry at 6, 18 and 36 months of age and cognition at 18 were analyzed. Mature
milk exhibited lower arachidonic acid (AA) and docosahexaenoic acid (DHA), among others, than
colostrum. Breast milk of non-normal weight mothers presented increased saturated FAs and n6:n3
ratio and decreased a-linolenic acid (ALA), DHA and monounsaturated FAs. Infant BMI-for-age
at 6 months of age was inversely associated with colostrum n6 (e.g., AA) and n3 (e.g., DHA) FAs
and positively associated with n6:n3 ratio. Depending on the maternal weight, infant cognition was
positively influenced by breast milk linoleic acid, n6 PUFAs, ALA, DHA and n3 LC-PUFAs, and
negatively a ected by n6:n3 ratio. In conclusion, this study shows that maternal pre-pregnancy BMI
can influence breast milk FAs and infant growth and cognition, endorsing the importance of a healthy
weight in future generations.This research was funded by the European Commission (DynaHEALTH-HORIZON 2020GANo: 633595)
and the Spanish Ministry of Economy and Competitiveness (BFU2012-40254-C03-02). Further support was obtained
from, Spanish Ministry of Innovation and Science (Junta de Andalucía), Excellence Projects (P06-CTS-02341).
ADLGP thanks the Mexican government and the National Council on Science and Technology (CONACYT) for
her PhD grant. The funders had no role in the study design, data collection, data analysis, decision to publish, or
preparation of the manuscript
Flipped Classroom i satisfacció de l'alumnat: una alternativa a les classes magistrals
Podeu consultar la Vuitena trobada de professorat de Ciències de la Salut completa a: http://hdl.handle.net/2445/66524En la classe invertida o flipped classroom bona part de la responsabilitat de l’ensenyament-aprenentatge recau en l’alumnat . El professorat elabora el material d’estudi que haurà de preparar l’alumnat abans de classe. En el nostre cas, posteriorment, a l’aula es treballa en petits grups, per contrastar el treball individual, resoldre dubtes, avaluacio per parells i en general, construir l’aprenentatge a partir d’un seguit d’estratègies protocol•litzades, que comporten quantitat de treball i un grau important de satisfaccio tant per a l'alumne com per al professorat
Changes in plasma fatty acid composition are associated with improvements in obesity and related metabolic disorders: A therapeutic approach to overweight adolescents
“This is an original manuscript published by Churchill Livingstone in Clinical Nutrition on February 2018, available at: doi: 10.1016/j.clnu.2016.11.006.”Background & aims: In recent years, obesity has reached alarming levels among children and adolescents. The study of plasma fatty acid (FA) composition, as a reflection of diet, and its associations with other parameters, that are closely linked to obesity and the cardiometabolic profile, may be useful for setting nutritional goals for obesity treatment and prevention. This study explored the role of plasma FA levels as modulators of body fat and cardiometabolic risk markers, in overweight adolescents.
Methods: A multidisciplinary weight loss program was followed by 127 overweight and obese adolescents aged 12-17 years old. Plasma FA composition, anthropometric indicators of adiposity and biochemical parameters were analyzed at baseline, two months (the end of the intensive intervention phase) and six months (the end of the extensive phase).
Results: While saturated fatty acid (SFA) and n-6 polyunsaturated fatty acid (PUFA) levels decreased significantly during the intervention, monounsaturated fatty acid (MUFA) and n-3 PUFA showed the opposite trend. The decrease in SFA C14:0 was associated with a reduction in total and LDL cholesterol, apolipoprotein B and insulin. The increase in MUFAs, especially C18:1n-9, was related to a reduction in weight, fat mass, fat mass index and glucose. Regarding PUFAs, changes in the n-3 series were not associated with any of the parameters studied, whereas the reduction in n-6 PUFAs was directly related to weight, fat mass, total and HDL cholesterol, apolipoprotein A1, glucose and insulin, and inversely associated with diastolic blood pressure. The adolescents with greater weight loss presented significant changes in MUFAs, n-6 PUFAs and C14:0.
Conclusions: Modifications in plasma FA composition could help modulate adiposity and the cardiometabolic profile in anti-obesity programs aimed at adolescents. The changes observed in FA composition were related to the success of the treatment, since the individuals most affected by these variations were those who presented the greatest weight loss.This work is part of the EVASYON study funded by the Spanish 326 Ministry of Health and Consumption (Carlos III Institute of Health. FIS. Grant PI 051579). The EVASYON study has received the award from AESAN (Spanish Agency for Food Security and Nutrition) from the Spanish Ministry of Health and Consumption to the best applied research project in 2009
Recommended from our members
Polyphenol intake and mortality risk: a re-analysis of the PREDIMED trial
Background: Polyphenols may lower the risk of cardiovascular disease (CVD) and other chronic diseases due to their antioxidant and anti-inflammatory properties, as well as their beneficial effects on blood pressure, lipids and insulin resistance. However, no previous epidemiological studies have evaluated the relationship between the intake of total polyphenols intake and polyphenol subclasses with overall mortality. Our aim was to evaluate whether polyphenol intake is associated with all-cause mortality in subjects at high cardiovascular risk. Methods: We used data from the PREDIMED study, a 7,447-participant, parallel-group, randomized, multicenter, controlled five-year feeding trial aimed at assessing the effects of the Mediterranean Diet in primary prevention of cardiovascular disease. Polyphenol intake was calculated by matching food consumption data from repeated food frequency questionnaires (FFQ) with the Phenol-Explorer database on the polyphenol content of each reported food. Hazard ratios (HR) and 95% confidence intervals (CI) between polyphenol intake and mortality were estimated using time-dependent Cox proportional hazard models. Results: Over an average of 4.8 years of follow-up, we observed 327 deaths. After multivariate adjustment, we found a 37% relative reduction in all-cause mortality comparing the highest versus the lowest quintiles of total polyphenol intake (hazard ratio (HR) = 0.63; 95% CI 0.41 to 0.97; P for trend = 0.12). Among the polyphenol subclasses, stilbenes and lignans were significantly associated with reduced all-cause mortality (HR =0.48; 95% CI 0.25 to 0.91; P for trend = 0.04 and HR = 0.60; 95% CI 0.37 to 0.97; P for trend = 0.03, respectively), with no significant associations apparent in the rest (flavonoids or phenolic acids). Conclusions: Among high-risk subjects, those who reported a high polyphenol intake, especially of stilbenes and lignans, showed a reduced risk of overall mortality compared to those with lower intakes. These results may be useful to determine optimal polyphenol intake or specific food sources of polyphenols that may reduce the risk of all-cause mortality. Clinical trial registration ISRCTN35739639
- …